Vinogradova S., Zhudenkov K., Benson N., Van Der Graaf P., Demin O., Karelina T. Prediction of long-term treatment outcome in HCV following 24 day PEG-IFN alpha-2b therapy using population pharmacokinetic-pharmacodynamic mixture modeling and classification analysis. Journal of theoretical biology. 2015. v.382, p.91-98.
Kolobkov D., Demin O., Metelkin E. Comparison of Asymptotic Confidence Sets for Regression in Small Samples. J Biopharm Stat. 2015 Jun 22. (Epub ahead of print).
Demin Jr O, Yakovleva T, Kolobkov D and Demin O. Analysis of efficacy of SGLT2 inhibitors using semi-mechanistic model. 2014 Front. Pharmacol. 5, 218.
Benson N, Metelkin E, Demin O, Li GL, Nichols D, van der Graaf PH. A systems pharmacology perspective on the clinical development of Fatty Acid amide hydrolase inhibitors for pain. 2014 CPT Pharmacometrics Syst Pharmacol. 3, e91.
Smirnov S., Metelkin E., Gizzatkulov N., Stepanov O., Demin O. "Towards Modeling of Metabolic Syndrome: Tissue Crosstalk in Lipid Spillover" in "A Systems Biology Approach to Study Metabolic Syndrome" Springer 2014 p.341.
Demin O, Karelina T, Svetlichniy D, Metelkin E, Speshilov G, Demin O Jr, Fairman D, van der Graaf PH, Agoram BM. Systems pharmacology models can be used to understand complex pharmacokinetic-pharmacodynamic behavior: an example using 5-lipoxygenase inhibitors. 2013 CPT Pharmacometrics Syst Pharmacol. 2, e74.
Thank you for your message! We will get back to you shortly.
First
Prev